Antigens for Recombinant DNA Vaccine

These vaccines operate by incorporating specific pathogen antigen genes into host cells to produce the corresponding antigen proteins that initiate a targeted immune response. The approach eliminates dangers tied to active and inactive viruses while enabling rapid production of vaccines for emerging infections.

Development of recombinant DNA vaccines requires careful selection of appropriate antigens. Host immune defenses develop lasting protection against certain infectious agents when antigens are properly selected to trigger immune memory. Through molecular biology and genetic engineering technology progress recombinant DNA vaccines have become essential tools in disease prevention research and therapy development for humans as well as animals.

DNA vaccine antigens show structural and functional traits that lead scientists to classify them into three basic groups.

Surface Antigens

Pathogen outer surfaces contain surface antigens which bind to host cell receptors and activate immune system activity.

• SARS-CoV-2 Spike Protein: The Spike protein functions as the primary viral entry route and research targets for DNA vaccine development.

Explore SARS-CoV-2 S Protein Antigens

• Hepatitis B Virus (HBV): The hepatitis B vaccine contains HBsAg that yeast expression systems produce to create highly immunogenic virus-like particles.

Go to HBsAg Antigens

• Human Papillomavirus (HPV): Virus-like particles generated from yeast and insect cells expressing HPV L1 protein protect against HPV infections while reducing cervical cancer and other HPV-related cancer incidences.

• Influenza A Virus:
  • Recombinant HA Protein: Mammalian and insect cell expression systems produce this protein which generates neutralizing antibodies against influenza viruses and provides both high production efficiency and extensive immune coverage to effectively combat influenza virus variability.
• Influenza B Virus:
  • Recombinant HA Protein: Researchers are developing recombinant HA proteins that target Influenza B to improve vaccine effectiveness and extend protection beyond current methods.

See our IBV HA Products

Subunit Antigens

These antigens typically consist of specific pathogen protein fragments that induce a focused immune response.

• MUC1 Antigen: The transmembrane glycoprotein MUC1 shows abnormal expression patterns across different types of cancer. MUC1 fragments hold the potential to trigger immune recognition which leads to tumor cell destruction and they present novel approaches for cancer immunotherapy.
• KRAS Mutation Antigen: KRAS gene mutations frequently occur in multiple types of cancer. Scientists are developing vaccines that target KRAS gene mutations to prevent high-risk cancers including pancreatic cancer.
• SARS-CoV-2 Nucleocapsid Protein (N): The coronavirus structural protein N protein is currently under investigation in DNA vaccines for its potential to trigger cell-mediated immune responses.

Go to SARS-CoV-2 NP Antigens

• Swine Vaccines:
  • Mycoplasma hyopneumoniae:
    Recombinant P97 Adhesin Protein: Subunit vaccines use this protein to generate antibody responses throughout the body as well as locally.
  • Transmissible Gastroenteritis Virus (TGEV):
    Recombinant TGEV S Protein: DNA and adenoviral vector vaccines generate both humoral and cell-mediated immune responses.

Recombinant TGEV S1 Protein [His] (DAG-WT2275)

Inquiry

• Tumor-Associated Antigens (e.g., HER2, CEA): Tumor-associated antigens trigger immune recognition of cancer cells which provides innovative approaches for cancer immunotherapy.

Contact Us for Expert Support

The process of developing vaccines involves multiple intricate challenges which demand the knowledge of experts. Our expert team stands ready to provide technical consultation and product support which will help improve your research work.

• Online Consultation: Use the "Online Inquiry" form located at the bottom of each product page to enter your requirements. Our team will reach out to you promptly.
• Contact Us: You can find contact information for our global offices on the "Contact Us" page if you want to communicate directly with our specialists.

Our company delivers high-quality antigen products and expert technical support for research on human vaccines, animal vaccines and cancer immunotherapies. We need to join forces to move vaccine development forward.

SARS-CoV-2 S Protein Antigens

HBV Surface Antigens

HPV L1 Antigens

Influenza HA Antigens

FeLV Antigens

RABV Glycoprotein Antigens

MUC1 Antigens